These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Novel agents in the treatment of non-small cell lung cancer: implications for neoadjuvant chemotherapy? Bergqvist M; Henriksson R; Brattström D In Vivo; 2005; 19(3):523-33. PubMed ID: 15875771 [TBL] [Abstract][Full Text] [Related]
6. Targeted therapies and non-small-cell lung cancer: new developments. Gridelli C Curr Opin Oncol; 2007 Mar; 19(2):75-7. PubMed ID: 17272976 [No Abstract] [Full Text] [Related]
7. Use of novel second-line targeted therapies in non-small cell lung cancer. Massarelli E; Herbst RS Semin Oncol; 2006 Feb; 33(1 Suppl 1):S9-16. PubMed ID: 16472704 [TBL] [Abstract][Full Text] [Related]
8. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. John T; Liu G; Tsao MS Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292 [TBL] [Abstract][Full Text] [Related]
9. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Jänne PA; Johnson BE Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820 [TBL] [Abstract][Full Text] [Related]
10. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Chou TY; Chiu CH; Li LH; Hsiao CY; Tzen CY; Chang KT; Chen YM; Perng RP; Tsai SF; Tsai CM Clin Cancer Res; 2005 May; 11(10):3750-7. PubMed ID: 15897572 [TBL] [Abstract][Full Text] [Related]
11. Targeted therapy for nonsmall cell lung cancer: focusing on angiogenesis, the epidermal growth factor receptor and multikinase inhibitors. Kotteas EA; Charpidou AG; Syrigos KN Anticancer Drugs; 2010 Feb; 21(2):151-68. PubMed ID: 20016368 [TBL] [Abstract][Full Text] [Related]
12. Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancer. Ettinger DS Oncologist; 2006 Apr; 11(4):358-73. PubMed ID: 16614231 [TBL] [Abstract][Full Text] [Related]
13. Targeting the growth factors and angiogenesis pathways: small molecules in solid tumors. Berz D; Wanebo H J Surg Oncol; 2011 May; 103(6):574-86. PubMed ID: 21480252 [TBL] [Abstract][Full Text] [Related]
14. Emerging therapeutic targets in non-small cell lung cancer. Dy GK; Adjei AA Proc Am Thorac Soc; 2009 Apr; 6(2):218-23. PubMed ID: 19349491 [TBL] [Abstract][Full Text] [Related]
15. Targeted therapies and non-small-cell lung cancer: work in progress? Gridelli C Curr Opin Oncol; 2006 Mar; 18(2):132-4. PubMed ID: 16462181 [No Abstract] [Full Text] [Related]